RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its first
quarter 2012 financial results will be released on Monday, May 7, 2012.
BioCryst will host a conference call and webcast at 11:00 a.m. Eastern
Time to discuss the financial results and to provide an update on the
Company's programs. The call will be led by Jon
P. Stonehouse, President and Chief Executive Officer, Thomas
R. Staab, II, Senior Vice President and Chief Financial Officer and Dr.
William P. Sheridan, Senior Vice President and Chief Medical Officer.
The webcast can be accessed by logging onto www.BioCryst.com.
Please connect to the website at least 15 minutes prior to the
conference call to ensure adequate time for any software download that
may be needed. To participate in the conference call, please dial
1-877-303-8027 (United States) or 1-760-536-5165 (International). No
passcode is needed for the call. The audio portion of the webcast will
be archived and available for replay for at least 14 days.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small
molecule drugs that block key enzymes involved in infectious and
inflammatory diseases. BioCryst currently has two late-stage development
programs: peramivir,
a viral neuraminidase inhibitor for the treatment of influenza, and BCX4208,
a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of
gout. In addition, BioCryst is advancing two preclinical programs
towards IND filings: BCX5191,
a nucleoside analog inhibitor of HCV RNA polymerase (NS5B) for hepatitis
C, and BCX4161,
an oral inhibitor of plasma kallikrein for hereditary angioedema.
Utilizing state-of-the-art structure-guided drug design and
crystallography, BioCryst continues to discover innovative compounds
with the goal of addressing unmet medical needs of patients and
physicians. For more information, please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including
statements regarding future results and achievements. These statements
involve known and unknown risks, uncertainties and other factors which
may cause our actual results, performance or achievements to be
materially different from any future results, performances or
achievements expressed or implied by the forward-looking statements.
Please refer to the documents BioCryst files periodically with the SEC
and located at http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
BioCryst Pharmaceuticals
Robert Bennett, +1-919-859-7910
Source: BioCryst Pharmaceuticals
News Provided by Acquire Media